RecruitingPhase 2NCT04804007
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Studying Malignant germ cell tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nabil Adra
- Principal Investigator
- Nabil Adra, MDIndiana University
- Intervention
- Etoposide(drug)
- Enrollment
- 64 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (1)
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04804007 on ClinicalTrials.govOther trials for Malignant germ cell tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT04038619Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT02830724Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersNational Cancer Institute (NCI)